(4-(3-Bromopropoxy)phenyl)boronic acid, 95.0%, 25g

Methyl 4-Iodosalicylate>98.0%(GC)5g

2-Chloro-4-cyanopyridine, 98.0%, 100g

(2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal, 97.0%, 100g

tert-Butyl (1R,5S,6s)-6-ethynyl-3-azabicyclo[3.1.0]hexane-3-carboxylate, 98%, 1g

3-(4-AMINOPHENYL)-1,1,3-TRIMETHYL-2,3-DIHYDRO-1H-INDEN-5-AMINE, 95%, 100g

6-Chloro-7-nitro-quinoxaline-2,3-diol, 95.0%, 500mg

(6-(Difluoromethoxy)pyridin-3-yl)methanamine, 95.0%, 100mg

3-Bromo-5-chloropyridine-4-carboxaldehyde, 95%, 1g

5-(Difluoromethoxy)pyridin-2-amine, 95+%, 1g

3-Benzoimidazol-1-yl-2-methyl-propionic acid, 95.0%, 1g

5-Bromo-3-picoline, 97.0%, 500g

Closing caps SILICOSEN®, C-40, Gesch. front, 27-40 mm 10 pcs